Journal of Clinical Medicine (Oct 2020)

Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy

  • Koji Ishida,
  • Tadashi Namisaki,
  • Koji Murata,
  • Yuki Fujimoto,
  • Souichi Takeda,
  • Masahide Enomoto,
  • Hiroyuki Ogawa,
  • Hirotetsu Takagi,
  • Yuki Tsuji,
  • Daisuke Kaya,
  • Yukihisa Fujinaga,
  • Masanori Furukawa,
  • Yasuhiko Sawada,
  • Koh Kitagawa,
  • Shinya Sato,
  • Norihisa Nishimura,
  • Hiroaki Takaya,
  • Kosuke Kaji,
  • Naotaka Shimozato,
  • Hideto Kawaratani,
  • Kei Moriya,
  • Takemi Akahane,
  • Akira Mitoro,
  • Hitoshi Yoshiji

DOI
https://doi.org/10.3390/jcm9113510
Journal volume & issue
Vol. 9, no. 11
p. 3510

Abstract

Read online

A potential restriction of the Baveno VI consensus, which helps to avoid unnecessary endoscopies, is the limited availability of FibroScan. We aimed to identify serum fibrosis indices that might aid in ruling out the presence of high-risk varices in cirrhotic patients. This retrospective study included 541 consecutive patients with cirrhosis who underwent endoscopy and had data available for nine serum fibrosis indices, including platelet count, hyaluronic acid, 7S fragment of type 4 collagen, procollagen type III N-terminal peptide, tissue inhibitor of metalloproteinases 1, Mac-2 binding protein glycosylation isomer, fibrosis index based on four factors (FIB-4), aspartate transaminase/platelet ratio index and enhanced liver fibrosis score. Optimal index cutoffs for predicting high-risk varices were calculated in an estimation cohort (n = 127) and evaluated in a validation cohort (n = 351). The diagnostic performance of the indices was assessed by receiver operating characteristic curve analysis. In the estimation cohort, a FIB-4 cutoff of 2.78 provided the greatest diagnostic accuracy in predicting both all-grade and high-risk varices. FIB-4 had a negative predictive value of 1.00 for high-risk varices in both cohorts, and 21.3% (27/127) and 14.8% (52/351) of the estimation and validation cohorts, respectively, avoided esophagogastroduodenoscopy; no high-risk varices were missed in either cohort. FIB-4 correctly identifies the absence of high-risk varices in patients with cirrhosis. Therefore, those with a FIB-4 of ≥2.78 should undergo esophagogastroduodenoscopy, and FIB-4 determination should be recommended every 6–12 months concurrently with the other blood tests until the index value reaches 2.78 in those with a FIB-4 of <2.78.

Keywords